BOEHMERT & BOEHMERT
Waiver for Covid Patents: Bleak future for biopharma industry?
The U.S., EU, India, and South Africa have reached an agreement on “key elements” of an IP waiver for COVID-19 vaccines that needs to be finalized and approved by WTO members.
What are the consequences of this IP expropriation for biopharma industry and for new medicines the world needs? What must be improved to prevent irrational fixation on weakening IP that is distracting from the real challenges that need to be overcome to provide access to new medicines to all?
Dr. Ute Kilger, German and European Patent and Trademark Attorney, Partner, BOEHMERT & BOEHMERT
- Jürgen M Schneider, BIO Deutschland e. V., Co-Chair Working Group Intellectual Property Rights /QIAGEN Hamburg GmbH, VP, Global IP & Licensing
- Dr. Rainer Strohmenger, Managing Partner, Wellington Partners
- Uwe Wolff, NAÏMA Strategic Legal Services GmbH Berlin / Brüssel
IP rights are our core competency
As one of the largest law firms for Intellectual Property (IP) in Europe, we offer our clients all services relating to IP. We focus on individual business needs and provide an optimal solution to the benefit of our clients. Our team of attorneys and patent attorneys with formidable legal talent across all technical and legal IP areas develops customized, creative, and practical solutions that meet our clients’ requirements.